Pancreatic cancer is a malignant tumor with difficulty in diagnosis and treatment and was the sixth leading cause of cancer death among both men and women in China. The 5-year relative survivals of pancreatic cancer were only 7.2% in China and the lowest level in all cancers. The proportion of estimated new cases of pancreatic cancer in China was comparatively high in East China, Northeast, North China, and Northwest and relatively low in Central China, Southwest, and South China, showing obvious regional characteristics. It implies that the incidence and mortality in the eastern region are significantly higher than those in the western region, which is consistent with the result that the incidence and mortality increased from low to middle to high urbanization areas in China, and the prevalence of diabetes increased from underdeveloped to intermediately developed to developed region.
From the *School of Pharmacy and Medical Technology,
†Key Laboratory of Pharmaceutical Analysis and Laboratory Medicine, and
‡Key Laboratory of Translational Cancer Research in University of Fujian Province, Putian University, Putian; and
§Department of Pathology, First Affiliated Hospital of Fujian Medical University;
∥Department of Priority Laboratory for Zoonoses Research, Fujian Provincial Center for Disease Control and Prevention;
¶Department of Reproductive Medicine Centre, First Affiliated Hospital of Fujian Medical University; and
#School of Pharmacy, Fujian Medical University, Fuzhou, China.
Received for publication June 6, 2018; accepted November 12, 2018.
Address correspondence to: Chengfei Zhao, MD, Department of Pharmacy, School of Pharmacy and Medical Technology, Putian University, 1133 Xueyuan Road, Chengxiang District, Putian 351100, China (e-mail: firstname.lastname@example.org).
This work was supported by Natural Science Foundation of Fujian Province (2017J01547), Open Project of Key Laboratory of Translational Cancer Research in University of Fujian Province (Putian University) (2018KF002) and National Natural Science Foundation of China (81571613 and 81572442).
The authors declare no conflict of interest.